about
Evaluation of 111In-labeled cyclic RGD peptides: tetrameric not tetravalent2-Mercaptoacetylglycylglycyl (MAG2) as a bifunctional chelator for 99mTc-labeling of cyclic RGD dimers: effect of technetium chelate on tumor uptake and pharmacokineticsIn vitro and in vivo analysis of indocyanine green-labeled panitumumab for optical imaging-a cautionary taleMinimizing liver uptake of cationic Tc radiotracers with ether and crown ether functional groupsEvaluation of 64Cu-labeled acridinium cation: a PET radiotracer targeting tumor mitochondria.64Cu-labeled lissamine rhodamine B: a promising PET radiotracer targeting tumor mitochondria.Evaluation of In-Labeled Cyclic RGD Peptides: Effects of Peptide and Linker Multiplicity on Their Tumor Uptake, Excretion Kinetics and Metabolic Stability.Evaluation of 99mTc-labeled cyclic RGD peptide with a PEG4 linker for thrombosis imaging: comparison with DMP444.Synthesis and characterization of gadolinium-Peptidomimetic complex as an αvβ3 integrin targeted MR contrast agent.Preparation of cystamine core dendrimer and antibody-dendrimer conjugates for MRI angiographyEvaluation of 99mTc-labeled cyclic RGD dimers: impact of cyclic RGD peptides and 99mTc chelates on biological properties.Synthesis and characterization of αvβ₃-targeting peptidomimetic chelate conjugates for PET and SPECT imaging.Evaluation of cetuximab as a candidate for targeted α-particle radiation therapy of HER1-positive disseminated intraperitoneal disease.(111)In- and (203)Pb-Labeled Cyclic RGD Peptide Conjugate as an α(v)β(3) Integrin-Binding RadiotracerColigand effects on the solution stability, biodistribution and metabolism of the (99m)Tc-labeled cyclic RGDfK tetramerImpact of bidentate chelators on lipophilicity, stability, and biodistribution characteristics of cationic 99mTc-nitrido complexesImpact of PKM linkers on biodistribution characteristics of the 99mTc-labeled cyclic RGDfK dimerA novel ternary ligand system useful for preparation of cationic (99m)Tc-diazenido complexes and (99m)Tc-labeling of small biomolecules.Improving tumor uptake and excretion kinetics of 99mTc-labeled cyclic arginine-glycine-aspartic (RGD) dimers with triglycine linkersImproving tumor-targeting capability and pharmacokinetics of (99m)Tc-labeled cyclic RGD dimers with PEG(4) linkers.64Cu-labeled 2-(diphenylphosphoryl)ethyldiphenylphosphonium cations as highly selective tumor imaging agents: effects of linkers and chelates on radiotracer biodistribution characteristicsImproving tumor uptake and pharmacokinetics of (64)Cu-labeled cyclic RGD peptide dimers with Gly(3) and PEG(4) linkersEvaluation of (64)Cu(DO3A-xy-TPEP) as a potential PET radiotracer for monitoring tumor multidrug resistance.Gene expression profiling upon (212) Pb-TCMC-trastuzumab treatment in the LS-174T i.p. xenograft model.Comparative studies on the therapeutic benefit of targeted α-particle radiation therapy for the treatment of disseminated intraperitoneal disease.99mTc-labeled cyclic RGD peptides for noninvasive monitoring of tumor integrin αVβ3 expression.Impact of bifunctional chelators on biological properties of 111In-labeled cyclic peptide RGD dimers.99mTcO(MAG2-3G3-dimer): a new integrin alpha(v)beta(3)-targeted SPECT radiotracer with high tumor uptake and favorable pharmacokinetics.Effects of targeting moiety, linker, bifunctional chelator, and molecular charge on biological properties of 64Cu-labeled triphenylphosphonium cations.99mTc-labeling of HYNIC-conjugated cyclic RGDfK dimer and tetramer using EDDA as coligand.64Cu-Labeled triphenylphosphonium and triphenylarsonium cations as highly tumor-selective imaging agents.Evaluation of a (99m)Tc-labeled cyclic RGD tetramer for noninvasive imaging integrin alpha(v)beta3-positive breast cancer.Effect of coligands on biodistribution characteristics of ternary ligand 99mTc complexes of a HYNIC-conjugated cyclic RGDfK dimer.Evaluation of 99mTcN-15C5 as a new myocardial perfusion imaging agent in normal dogs and canines with coronary stenosis.Tc-99m-N-MPO: novel cationic Tc-99m radiotracer for myocardial perfusion imaging.Evaluation of novel cationic (99m)Tc-nitrido complexes as radiopharmaceuticals for heart imaging: improving liver clearance with crown ether groups.
P50
Q33867187-7CB6A874-5334-4DB2-BA3A-56AF33538202Q33925952-4518939A-915A-465B-A2BC-09C8D3DCBA4BQ34343535-323FBC5B-36DC-4346-B030-8ACFB8CB8E6EQ34391531-197F8053-93C4-4703-AEE2-235332D65E8CQ34906397-D088E77D-2AC7-42DF-AD5C-EEA66D974F74Q35141767-92C53263-5548-422C-B310-99BC0511B8BFQ35167459-F3996AEC-98D8-4A60-9AAA-3D360FC7CDC4Q35169184-9BDF3416-D6C0-4102-843E-5FB7E4E333D6Q35561603-5A52A999-B6BA-4334-BDD2-2747CB01CB9EQ35605967-99ED1CC6-C1E6-4E19-A06E-10D9D75E2830Q35846395-A5CB194D-B59A-4416-AFB0-367579B63FE4Q36177190-1D44279A-685E-481A-86CD-52E5ABA77BEBQ36213374-734958A3-99D5-483A-B574-CF59C73C6541Q36393648-EB2A3341-9A46-454A-8830-6C77EDE0EC5FQ36515561-F1EC1646-50E7-4CFB-846E-554A275D47F4Q36843952-BF707BD5-D182-45DD-81FE-FA620D3C8F6AQ36924767-70E85A5F-83E9-4552-9E8F-5A1B06775A11Q37003389-C16CE57D-0D7D-4D07-A761-7CBE265BFF7EQ37060623-32988061-E2BC-46A4-9945-532D6416A853Q37081396-7BADFFBA-4388-497C-B5A6-4E32058923BEQ37088807-F9A3915B-190D-4C60-8B6F-26E0F28E7100Q37178786-00B1765E-3DF9-497C-B58A-CD32F72D8E64Q37260774-49CA9803-E7FD-4F27-8639-CD0EBC2206F3Q37482554-45ABBB66-DE3F-4639-929A-A559B395FE92Q38663041-1A4CB0BA-AD4E-4B95-A8CF-81572140A0A0Q39552569-8902B7AF-3236-468A-9A9C-69D80E93595CQ39755513-C07C99B6-2C09-4538-ADD3-B6C783E010BCQ39844585-8D3B83F8-D60D-43A5-90BE-F80D2E57CC0FQ39991060-6DFA5318-E126-4D3C-8888-3AE4CE4DBDE5Q40011918-1A715B5A-49FA-4F3E-9018-EA67152370CDQ40080668-2293869F-2D52-4AA6-827C-5488746D2626Q40162799-47AD6DBD-604A-4EC9-90B0-B0C7A339E1DDQ40351589-92096819-5716-483A-8DEF-D29E2452B359Q46447876-F39D2F63-C0FF-47EE-8583-33DFBEEE6DECQ46601920-708D7B3F-F678-4392-8BF0-5BEAFC29B8BCQ48706545-CFFFFB21-D1CD-4948-9856-367E1DD9DF70
P50
name
Young-Seung Kim
@en
Young-Seung Kim
@nl
type
label
Young-Seung Kim
@en
Young-Seung Kim
@nl
prefLabel
Young-Seung Kim
@en
Young-Seung Kim
@nl